Therapie der Migräneattacke und Prophylaxe der Migräne

 

 

Scroll to top

• Literatur

• 1 Diener HC. Leitlinien für Diagnostik und Therapie in der Neurologie: Herausgegeben von der Kommission Leitlinien der DGN. Stuttgart: Georg Thieme Verlag; 2012.
• 2 Kropp P, Meyer B, Dresler T, Fritsche G, Gaul C, Niederberger U. et al. [Relaxation techniques and behavioural therapy for the treatment of migraine: Guidelines from the German Migraine and Headache Society]. Schmerz 2017; 31 (05) 433-47.
• 3 Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A. et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009; 16 (09) 968-81.
• 4 Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1346-53.
• 5 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 08 (17) 1337-45.
• 6 Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN. et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012; 39 (2 Suppl 2): S1-59.
• 7 Lanteri-Minet M, Valade D, Geraud G, Lucas C, Donnet A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain 2014; 15: 2.
• 8 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia 2018; 38 (01) 1-211.
• 9 Riesco N, Perez-Alvarez AI, Verano L, Garcia-Cabo C, Martinez-Ramos J, Sanchez-Lozano P. et al. Prevalence of cranial autonomic parasympathetic symptoms in chronic migraine: Usefulness of a new scale. Cephalalgia 2016; 36 (04) 346-50.
• 10 Maytal J, Young M, Shechter A, Lipton RB. Pediatric migraine and the International Headache Society (IHS) criteria. Neurology 1997; 48 (03) 602-7.
• 11 Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68 (05) 343-9.
• 12 Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A. et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27 (03) 193-210.
• 13 Yoon MS, Katsarava Z, Obermann M, Fritsche G, Oezyurt M, Kaesewinkel K. et al. Prevalence of primary headaches in Germany: results of the German Headache Consortium Study. J Headache Pain 2012; 13 (03) 215-23.
• 14 Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11 (04) 289-99.
• 15 Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015; 55 (01) 21-34.
• 16 Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010; 52 (12) 1088-97.
• 17 Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010; 30 (09) 1065-72.
• 18 Rosenberg JH, Silberstein SD. The headache of SAH responds to sumatriptan. Headache 2005; 45 (05) 597-8.
• 19 Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E. et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia 2014; 34 (04) 258-67.
• 20 Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A. et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache 2015; 55 Suppl 4: 221-35.
• 21 Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358 (9294) 1668-75.
• 22 Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a metaanalysis of 53 trials. Cephalalgia 2002; 22 (08) 633-58.
• 23 Xu H, Han W, Wang J, Li M. Network metaanalysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain 2016; 17 (01) 113.
• 24 Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E. et al. Comparative tolerability of treatments for acute migraine: A network metaanalysis. Cephalalgia 2017; 37 (10) 965-78.
• 25 Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 02: CD009663
• 26 Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 02: CD008615
• 27 Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 02: CD009665
• 28 Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012; 02: CD009664
• 29 Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17 (09) 53-67.
• 30 Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 2005; 19 (02) 125-36.
• 31 Gawel M, Aschoff J, May A, Charlesworth BR, Team RS. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine – results from phase 1 of the REALIZE Study. Headache 2005; 45 (01) 7-16.
• 32 Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst Rev 2014; 05: CD008616
• 33 Ferrari M. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 19 (Suppl. 23) 2-8.
• 34 Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA. et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14 (05) 330-8.
• 35 Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43 (04) 376-88.
• 36 Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks – a review of controlled clinical trials. Cephalalgia 1993; 13 (04) 238-44.
• 37 Mathew NT. Naratriptan: a review. Expert Opin Investig Drugs 1999; 08 (05) 687-95.
• 38 Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991; 325 (05) 316-21.
• 39 Becker W. A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Frontiers in Headache Research 1997; 06: 207-12.
• 40 Ryan R, Elkind A, Baker CC, Mullican W, De-Bussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997; 49 (05) 1225-30.
• 41 Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain 2011; 12 (04) 399-403.
• 42 Cortelli P, Allais G, Tullo V, Benedetto C, Zava D, Omboni S. et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol Sci 2011; 32 Suppl 1: S95-8.
• 43 Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA. et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998; 38 (10) 737-47.
• 44 Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W. et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998; 38 (10) 748-55.
• 45 Tfelt-Hansen P, Ryan Jr. RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000; 55 (9 Suppl 2): S19-24.
• 46 Ng-Mak DS, Hu XH, Bigal M. Migraine treatment with rizatriptan and almotriptan: a crossover study. Headache 2009; 49 (05) 655-62.
• 47 Diener HC. Eletriptan in migraine. Expert Rev Neurother 2005; 05 (01) 43-53.
• 48 Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D. et al. A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. J Headache Pain 2011; 12 (02) 219-26.
• 49 Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B. et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a doubleblind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain 2012; 13 (05) 401-6.
• 50 Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O’Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40 (07) 513-20.
• 51 Goldstein J, Tiseo PT, Albert KS, Li C, Sikes CR. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006; 46 (07) 1142-50.
• 52 Seeburger JL, Taylor FR, Friedman D, Newman L, Ge Y, Zhang Y. et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia 2011; 31 (07) 786-96.
• 53 Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T. et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24 (11) 947-54.
• 54 Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM. et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 2005; 45 (08) 973-82.
• 55 Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. The Lancet 1995; 346 (8980): 923-6.
• 56 Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache Pain 2012; 13 (08) 669-75.
• 57 Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 1999; 19 (04) 232-40.
• 58 Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebocontrolled trial. J Headache Pain 2007; 08 (03) 175-9.
• 59 Diamond ML, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004; 44 (03) 209-16.
• 60 Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 1999; 19 (06) 581-8 discussion 42.
• 61 The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol 1991; 31 (05) 314-22.
• 62 Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003; 49 (01) 20-9.
• 63 Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47 (02) 99-107.
• 64 Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007; 14 (03) 269-75.
• 65 Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ. et al. Sumatriptannaproxen for acute treatment of migraine: a randomized trial. JAMA 2007; 297 (13) 1443-54.
• 66 Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J. et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291 (08) 965-73.
• 67 Lipton RB, Dodick DW, Adelman JU, Kaniecki RG, Lener SE, White JD. et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009; 29 (08) 826-36.
• 68 Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016; 04: CD008541
• 69 Silberstein S, McDonald SA, Goldstein J, Aurora S, Lener SE, White J. et al. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia 2014; 34 (04) 268-79.
• 70 Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008; 48 (06) 921-30.
• 71 Tullo V, Valguarnera F, Barbanti P, Cortelli P, Sette G, Allais G. et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. Cephalalgia 2014; 34 (06) 434-45.
• 72 Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43 (07) 729-33.
• 73 Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin 2004; 20 (09) 1465-72.
• 74 Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004; 44 (04) 318-22.
• 75 Freitag F, Smith T, Mathew N, Rupnow M, Greenberg S, Mao L. et al. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. Headache 2008; 48 (03) 341-54.
• 76 Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H. et al. Early vs. non-early intervention in acute migraine-’Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 2008; 28 (04) 383-91.
• 77 Cady RK, Freitag FG, Mathew NT, Elkind AH, Mao L, Fisher AC. et al. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache 2009; 49 (03) 350-63.
• 78 Lanteri-Minet M, Diaz-Insa S, Leone M, Vila C, Clissold SP, Study S. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int J Clin Pract 2010; 64 (07) 936-43.
• 79 Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687-95.
• 80 Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R. et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia 2015; 35 (02) 118-31.
• 81 Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J. et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994; 44 (09) 1587-92.
• 82 Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11 (10) 671-7.
• 83 Hall G, Brown M, Mo J, MacRae K. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-8.
• 84 Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44 (07) 642-51.
• 85 Mathew PG, Krel R, Buddhdev B, Ansari H, Joshi SG, Spinner WD. et al. A retrospective analysis of triptan and the use for basilar and hemiplegic migraine. Headache. 2016
• 86 Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998; 32 (01) 33-8.
• 87 Sclar DA, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use: a risk for serotonin syndrome. Headache 2008; 48 (01) 126-9.
• 88 Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache 2010; 50 (06) 1089-99.
• 89 Tfelt-Hansen PC. Delayed absorption of many (paracetamol, aspirin, other NSAIDs and zolmitriptan) but not all (sumatriptan, rizatriptan) drugs during migraine attacks and most likely normal gastric emptying outside attacks. A review. Cephalalgia 2017; 37 (09) 892-901.
• 90 Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 1988; 08 (03) 139-47.
• 91 Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975; 02 (01) 57-63.
• 92 Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 2006; 46 (01) 57-63.
• 93 Saguil A, Herness J. Aspirin with or without antiemetic for acute migraine headaches in adults. American family physician 2014; 89 (03) 176-7.
• 94 Waelkens J. Domperidone in the prevention of complete classical migraine. Br Med J (Clin Res Ed) 1982; 284 (6320): 944.
• 95 Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984; 04 (02) 85-90.
• 96 Ross-Lee L, Heazlewood V, Tyrer JH, Eadie MJ. Aspirin treatment of migraine attacks: plasma drug level data. Cephalalgia 1982; 02 (01) 9-14.
• 97 Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 04 (02) 107-11.
• 98 MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993; 13 (02) 124-7.
• 99 Kirthi V, Derry S, Moore RA, McQuay HJ. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010; 04: CD008041
• 100 Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995; 02 (07) 597-602.
• 101 Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C. et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64 (03) 463-8.
• 102 Griffith JD, Mycyk MB, Kyriacou DN. Metoclopramide versus hydromorphone for the emergency department treatment of migraine headache. J Pain 2008; 09 (01) 88-94.
• 103 Salazar G, Fragoso M, Vergez L, Sergio P, Cuello D. Metoclopramide as an analgesic in severe migraine attacks: an open, single-blind, parallel control study. Recent Pat CNS Drug Discov 2011; 06 (02) 141-5.
• 104 Friedman BW, Mulvey L, Esses D, Solorzano C, Paternoster J, Lipton RB. et al. Metoclopramide for acute migraine: a dose-finding randomized clinical trial. Ann Emerg Med 2011; 57 (05) 475-82 e1.
• 105 Eken C. Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis. Am J Emerg Med 2015; 33 (03) 331-7.
• 106 Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 1990; 19 (10) 1083-7.
• 107 Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993; 22 (02) 191-5.
• 108 Coppola M, Yealy DM, Leibold RA. Randomized, Placebo-Controlled Evaluation of Prochlorperazine Versus Metoclopramide for Emergency Department Treatment of Migraine Headache. Annals of Emergency Medicine 1995; 26 (05) 541-6.
• 109 Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2005; 25 (03) 199-204.
• 110 Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med 1996; 14 (03) 262-4.
• 111 Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. Bmj 2004; 329 (7479): 1369-73.
• 112 Friedman BW, Garber L, Yoon A, Solorzano C, Wollowitz A, Esses D. et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology 2014; 82 (11) 976-83.
• 113 Balbin JE, Nerenberg R, Baratloo A, Friedman BW. Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am J Emerg Med 2016; 34 (04) 713-6.
• 114 Aube M. Migraine in pregnancy. Neurology 1999; 53 (4 Suppl 1): S26-8.
• 115 Huppert D, Strupp M, Muckter H, Brandt T. Which medication do I need to manage dizzy patients?. Acta oto-laryngologica 2011; 131 (03) 228-41.
• 116 Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989; 18 (04) 360-5.
• 117 Stiell IG, Dufour DG, Moher D, Yen M, Beilby WJ, Smith NA. Methotrimeprazine versus meperidine and dimenhydrinate in the treatment of severe migraine: a randomized, controlled trial. Ann Emerg Med 1991; 20 (11) 1201-5.
• 118 Teggi R, Colombo B, Gatti O, Comi G, Bussi M. Fixed combination of cinnarizine and dimenhy-drinate in the prophylactic therapy of vestibular migraine: an observational study. Neurol Sci 2015; 36 (10) 1869-73.
• 119 Friedman BW, Cabral L, Adewunmi V, Solorzano C, Esses D, Bijur PE. et al. Diphenhydramine as Adjuvant Therapy for Acute Migraine: An Emergency Department-Based Randomized Clinical Trial. Ann Emerg Med 2016; 67 (01) 32-9 e3.
• 120 Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009; 49 (01) 79-89.
• 121 Lecchi M, D’Alonzo L, Negro A, Martelletti P. Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert opinion on drug metabolism & toxicology 2014; 10 (10) 1381-95.
• 122 Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; 04: Cd008041
• 123 Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebocontrolled study. Cephalalgia 1994; 14 (04) 297-300.
• 124 Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 04. Cd008039.
• 125 Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF. et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, doseranging study. Cephalalgia 2000; 20 (04) 233-43.
• 126 Havanka-Kanniainen H. Treatment of acute migraine attack: ibuprofen and placebo compared. Headache 1989; 29 (08) 507-9.
• 127 Kloster R, Nestvold K, Vilming ST. A doubleblind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12 (03) 169-71 discussion 28.
• 128 Moore RA, Derry S, Wiffen PJ, Straube S, Aldington DJ. Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. European journal of pain (London, England) 2015; 19 (09) 1213-23.
• 129 Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013; 04: Cd008040
• 130 Leinisch E, Evers S, Kaempfe N, Kraemer C, Sostak P, Jurgens T. et al. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain 2005; 117 (03) 396-400.
• 131 Mehuys E, Paemeleire K, Crombez G, Adriaens E, Van Hees T, Demarche S. et al. The heterogeneity of headache patients who self-medicate: a cluster analysis approach. Pain 2016; 157 (07) 1464-71.
• 132 Diener HC, Pfaffenrath V, Pageler L, Peil H, Aicher B. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005; 25 (10) 776-87.
• 133 Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr., Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, doubleblind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006; 46 (03) 444-53.
• 134 Lipton RB, Stewart WF, Ryan RE Jr., Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998; 55 (02) 210-7.
• 135 Dong Z, Chen X, Steiner TJ, Hou L, Di H, He M. et al. Medication-overuse headache in China: clinical profile, and an evaluation of the ICHD-3 beta diagnostic criteria. Cephalalgia 2015; 35 (08) 644-51.
• 136 Da Silva AN, Lake 3rd AE. Clinical aspects of medication overuse headaches. Headache 2014; 54 (01) 211-7.
• 137 Mehuys E, Paemeleire K, Van Hees T, Christiaens T, Van Bortel L, Van Tongelen I. et al. [Self-medication of regular headache: a community pharmacy-based survey in Belgium]. Journal de pharmacie de Belgique 2012; 02: 4-10.
• 138 Scher AI, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia 2010; 30 (03) 321-8.
• 139 Trucco M, Meineri P, Ruiz L, Gionco M. Medication overuse headache: withdrawal and prophylactic therapeutic regimen. Headache 2010; 50 (06) 989-97.
• 140 Choi JC, Lee JS, Kang SY, Kang JH, Bae JM. Chronic daily headache with analgesics overuse in professional women breath-hold divers. Headache 2008; 48 (07) 1037-43.
• 141 Imai N, Kitamura E, Konishi T, Suzuki Y, Serizawa M, Okabe T. Clinical features of probable medication-overuse headache: a retrospective study in Japan. Cephalalgia 2007; 27 (09) 1020-3.
• 142 Trucco M, Meineri P, Ruiz L. Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain 2005; 06 (04) 334-7.
• 143 Cupini LM, Calabresi P. Medication-overuse headache: pathophysiological insights. J Headache Pain 2005; 06 (04) 199-202.
• 144 Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs 2004; 64 (22) 2503-14.
• 145 Diener HC, Peil H, Aicher B. The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2011; 31 (14) 1466-76.
• 146 Goldstein J, Hoffman HD, Armellino JJ, Battikha JP, Hamelsky SW, Couch J. et al. Treatment of severe, disabling migraine attacks in an over-thecounter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 1999; 19 (07) 684-91.
• 147 Silberstein SD. Menstrual migraine. J Womens Health Gend Based Med 1999; 08 (07) 919-31.
• 148 Karabetsos A, Karachalios G, Bourlinou P, Reppa A, Koutri R, Fotiadou A. Ketoprofen versus paracetamol in the treatment of acute migraine. Headache 1997; 37 (01) 12-4.
• 149 Allais G, De Lorenzo C, Airola G, Peano S, Benedetto C. [Dexketoprofen trometamol in the treatment of acute migraine attack]. Minerva Med 2000; 91 (7–8): 153-9.
• 150 Dib M, Massiou H, Weber M, Henry P, GarciaA-costa S, Bousser MG. et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002; 58 (11) 1660-5.
• 151 Tulunay FC, Ergun H, Gulmez SE, Ozbenli T, Ozmenoglu M, Boz C. et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. Funct Neurol 2004; 19 (03) 197-202.
• 152 Ramacciotti AS, Soares BG, Atallah AN. Dipyrone for acute primary headaches. Cochrane Database Syst Rev 2007; 02: CD004842
• 153 Göbel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks: a double-blind, placebo-controlled, randomized study. Cephalalgia 2004; 24: 888-93.
• 154 Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L. Non-prescription (OTC) oral analgesics for acute pain – an overview of Cochrane reviews. Cochrane Database Syst Rev 2015; 11: CD010794
• 155 Diener HC, Montagna P, Gacs G, Lyczak P, Schumann G, Zoller B. et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 2006; 26 (05) 537-47.
• 156 Massiou H, Serrurier D, Lasserre O, Bousser MG. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia 1991; 11 (02) 59-63.
• 157 Peroutka SJ, Lyon JA, Swarbrick J, Lipton RB, Kolodner K, Goldstein J. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache 2004; 44 (02) 136-41.
• 158 Engindeniz Z, Demircan C, Karli N, Armagan E, Bulut M, Aydin T. et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomised, double-blind study. J Headache Pain 2005; 06 (03) 143-8.
• 159 Del Bene E, Poggioni M, Garagiola U, Maresca V. Intramuscular treatment of migraine attacks using diclofenac sodium: a crossover clinical trial. J Int Med Res 1987; 15 (01) 44-8.
• 160 Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, Jordan DM. et al. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache 2005; 45 (10) 1317-27.
• 161 Totzeck A, Gaul C. [The role of opioids in the treatment of primary headache disorders]. Schmerz 2014; 28 (02) 135-40.
• 162 Evers S. The efficacy of triptans in childhood and adolescence migraine. Curr Pain Headache Rep 2013; 17 (07) 342.
• 163 Bonfert M, Straube A, Schroeder AS, Reilich P, Ebinger F, Heinen F. Primary headache in children and adolescents: update on pharmacotherapy of migraine and tension-type headache. Neuropediatrics 2013; 44 (01) 3-19.
• 164 Diener HC. for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, doubledummy, randomized, multicenter, parallel group study. Cephalalgia 1999; 19: 581-8.
• 165 Bigal ME, Bordini CA, Speciali JG. Intravenous metamizol (Dipyrone) in acute migraine treatment and in episodic tension-type headache – a placebo-controlled study. Cephalalgia 2001; 21 (02) 90-5.
• 166 Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache: The Journal of Head and Face Pain 2002; 42 (09) 862-71.
• 167 Lenaerts M, Bastings E, Sianard J, Schoenen J. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels. Acta Neurol Belg 1996; 96 (02) 126-9.
• 168 Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005; 45 (01) 42-6.
• 169 Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E. et al. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology 2017; 89 (20) 2075-82.
• 170 Elenbaas RM, Iacono CU, Koellner KJ, Pribble JP, Gratton M, Racz G. et al. Dose effectiveness and safety of butorphanol in acute migraine headache. Pharmacotherapy 1991; 11 (01) 56-63.
• 171 Hoffert MJ, Couch JR, Diamond S, Elkind AH, Goldstein J, Kohlerman 3rd NJ. et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995; 35 (02) 65-9.
• 172 Nicolodi M, Sicuteri F. Relief of migraine attack with N-methyl-D-aspartic acid receptor antagonist ketamine: a double blind comparison with placebo-theoretic implications. Cephalalgia 1996; 16: 372.
• 173 Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache 2000; 40 (03) 224-30.
• 174 Drummond-Lewis J, Scher C. Propofol: a new treatment strategy for refractory migraine headache. Pain Med 2002; 03 (04) 366-9.
• 175 Moshtaghion H, Heiranizadeh N, Rahimdel A, Esmaeili A, Hashemian H, Hekmatimoghaddam S. The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial. Pain practice: the official journal of World Institute of Pain 2015; 15 (08) 701-5.
• 176 Woldeamanuel YW, Rapoport AM, Cowan RP. The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 2015; 35 (11) 996-1024.
• 177 Amundsen S, Nordeng H, Nezvalova-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 2015; 11 (04) 209-19.
• 178 Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 2015; 55 (04) 490-501.
• 179 O’Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263 (1–2): 7-12.
• 180 Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17 (01) 1-7.
• 181 Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005; 25 (09) 685-8.
• 182 Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42 (04) 543-9.
• 183 Wood ME, Frazier JA, Nordeng HM, Lapane KL. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiol Drug Saf 2016; 25 (05) 493-502.
• 184 MacGregor EA, Victor TW, Hu X, Xiang Q, Puenpatom RA, Chen W. et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 2010; 50 (04) 528-38.
• 185 Cady RK, Diamond ML, Diamond MP, Ballard JE, Lener ME, Dorner DP. et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 2011; 51 (05) 664-73.
• 186 Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH. et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007; 47 (07) 1037-49.
• 187 Savi L, Omboni S, Lisotto C, Zanchin G, Ferrari MD, Zava D. et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, crossover, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain 2011; 12 (06) 609-15.
• 188 Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, Rapoport A. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008; 48 (09) 1286-93.
• 189 Melchart D, Linde K, Fischer P, White A, Allais G, Vickers A. et al. Acupuncture for recurrent headaches: a systematic review of randomized controlled trials. Cephalalgia 1999; 19 (09) 779-86 discussion 65.
• 190 Melchart D, Thormaehlen J, Hager S, Liao J, Linde K, Weidenhammer W. Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. J Intern Med 2003; 253 (02) 181-8.
• 191 Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A. et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10 (07) e0130733.
• 192 Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006; 59 (04) 652-61.
• 193 Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31 (05) 333-40.
• 194 Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22 (07) 491-512.
• 195 Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; 02: CD003225
• 196 Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN. et al. Prophylactic treatment of classical and non-classical migraine with metoprolol – a comparison with placebo. Cephalalgia 1983; 03 (04) 207-12.
• 197 Kangasniemi P, Andersen AR, Andersson PG, Gilhus NE, Hedman C, Hultgren M. et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 07 (04) 231-8.
• 198 Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallelgroups comparison with placebo and dose-ranging follow-up. Headache 1988; 28 (01) 15-23.
• 199 Wörz R, Reinhardt-Benmalek B, Föh M, Grotemeyer KH, Scharafinski HW. Prevention of migraine using bisoprolol. Results of a double-blind study versus metoprolol. Fortschr Med 1992; 110 (14) 268-272.
• 200 van de Ven LL, Franke CL, Koehler PJ. Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 1997; 17 (05) 596-9.
• 201 Briggs RS, Millac PA. Timolol in migraine prophylaxis. Headache 1979; 19 (07) 379-81.
• 202 Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. JAMA 1984; 252 (18) 2576-80.
• 203 Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69 (01) 1-8.
• 204 Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 1980; 20 (04) 204-7.
• 205 Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983; 23 (04) 188-90.
• 206 Johannsson V, Nilsson LR, Widelius T, Javerfalk T, Hellman P, Akesson JA. et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache 1987; 27 (07) 372-4.
• 207 Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K. Nebivolol and Metoprolol for Treating Migraine: An Advance on beta-Blocker Treatment?. Headache 2008; 48 (01) 118-25.
• 208 Nanda RN, Johnson RH, Gray J, Keogh HJ, Melville ID. A double blind trial of acebutolol for migraine prophylaxis. Headache 1978; 18 (01) 20-2.
• 209 Ekbom K. Alprenolol for migraine prophylaxis. Headache 1975; 15 (02) 129-32.
• 210 Ekbom K, Zetterman M. Oxprenolol in the treatment of migraine. Acta Neurol Scand 1977; 56 (02) 181-4.
• 211 Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. Acta Neurol Scand 1972; 48 (01) 124-8.
• 212 Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981; 21 (06) 235-9.
• 213 Manzoni GC, Bono G, Sacquegna T, Manna V, Lanfranchi M, Micieli G. et al. Flunarizine in common migraine: Italian cooperative trial. I. Short-term results and responders’ definition. Cephalalgia 1985; 05 (Suppl. 02) 149-53.
• 214 Baker C. Double-blind evaluation of flunarizine and placebo in the prophylactic treatment of migraine. Headache 1987; 27: 288.
• 215 Bono G, Manzoni GC, Martucci N, Baldrati A, Farina S, Cassabgi F. et al. Flunarizine in common migraine: Italian cooperative trial. II. Longterm follow-up. Cephalalgia 1985; 05 (Suppl. 02) 155-8.
• 216 Centonze V, Tesauro P, Trizio T, Magrone D, Vino M, Macinagrossa G. et al. Efficacy and tolerability of flunarizine in the prophylaxis of migraine. Cephalalgia 1985; 05 (Suppl. 02) 165-8.
• 217 Sorensen PS, Hansen K, Olesen J. A placebocontrolled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986; 06 (01) 7-14.
• 218 Diamond S, Freitag F. A double-blind trial of flunarizine in migraine prophylaxis. Headache Quarterly-Current Treatment and Research 1993; 04 (02) 169-72.
• 219 Gawel M, Kreeft J, Simard D, Nelson R. Flunarizine in the treatment of migraine with and without aura. Canadian J Neurol Sci 1993; 20 (Suppl. 02) S54.
• 220 Diener H. editor. Efficacy and tolerability of flunarizine and propranolol in the prophylactic treatment of migraine. Cephalalgia. 1999
• 221 Pfaffenrath V, Oestreich W, Haase W. Flunarizine (10 and 20 mg) i.v. versus placebo in the treatment of acute migraine attacks: a multicentre double-blind study. Cephalalgia 1990; 10 (02) 77-81.
• 222 Sorensen PS, Larsen BH, Rasmussen MJ, Kinge E, Iversen H, Alslev T. et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991; 31 (10) 650-7.
• 223 Diener H. Flunarizine for migraine prophylaxis. Drug Treatment of Migraine and Other Headaches. 17. Karger Publishers 2000; 269-78.
• 224 McArthur JC, Marek K, Pestronk A, McArthur J, Peroutka SJ. Nifedipine in the prophylaxis of classic migraine: a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 1989; 39 (2 Pt 1): 284-6.
• 225 European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Migraine-Nimodipine European Study Group (MINES).. Headache 1989; 29 (10) 633-8.
• 226 Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63 (12) 2215-24.
• 227 Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ. et al. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251 (08) 943-50.
• 228 Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebocontrolled trial. Headache 2007; 47 (02) 170-80.
• 229 Lainez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol 2007; 14 (08) 900-6.
• 230 Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-23.
• 231 Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B. et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007; 06 (12) 1054-62.
• 232 Krymchantowski AV, da Cunha CJevoux, Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. J Headache Pain 2012; 13 (01) 53-9.
• 233 Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17 (02) 103-8.
• 234 Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S. et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58 (11) 1652-9.
• 235 Janzen RWC, Gaul C. Migräneprophylaxe: Valproinsäure. Neues zum Off-label-use. Dtsch Ärzteblatt 2015; 112: 12.
• 236 Apostol G, Lewis DW, Laforet GA, Robieson WZ, Fugate JM, Abi-Saab WM. et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 2009; 49 (01) 45-53.
• 237 Apostol G, Pakalnis A, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM. et al. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents. Headache 2009; 49 (01) 36-44.
• 238 Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76 (12) 1730-2.
• 239 Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month openlabel study. Clin Neuropharmacol 2006; 29 (06) 338-42.
• 240 Sadeghian H, Motiei-Langroudi R. Comparison of Levetiracetam and sodium Valproate in migraine prophylaxis: A randomized placebo-controlled study. Ann Indian Acad Neurol 2015; 18 (01) 45-8.
• 241 Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17 (02) 109-12.
• 242 Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R. et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 2011; 34 (04) 174-7.
• 243 Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976; 26 (02) 121-7.
• 244 Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36 (11) 695-9.
• 245 Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Archives of Neurology 1987; 44 (05) 486-9.
• 246 Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36 (04) 684-90.
• 247 Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993; 50 (08) 825-30.
• 248 Lampl C, Huber G, Adl J, Luthringshausen G, Franz G, Marecek S. et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol 2009; 16 (08) 943-8.
• 249 Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M. et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, doubledummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31 (03) 542-59.
• 250 Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2010; 51 (01) 33-51.
• 251 Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35 (04) 500-4.
• 252 Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (01) 44-8.
• 253 Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (02) 144-52.
• 254 Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990; 264 (13) 1711-3.
• 255 Diener HC, Hartung E, Chrubasik J, Evers S, Schoenen J, Eikermann A. et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001; 21 (02) 120-8.
• 256 Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51 (02) 89-97.
• 257 Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63 (12) 2240-4.
• 258 Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. Investigators The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a doubleblind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22 (07) 523-32.
• 259 Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention – a randomized, doubleblind, multicentre, placebo-controlled study. Cephalalgia 2005; 25 (11) 1031-41.
• 260 Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH. et al. Magnesium in the prophylaxis of migraine – a double-blind placebo-controlled study. Cephalalgia 1996; 16 (06) 436-40.
• 261 Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebocontrolled and double-blind randomized study. Cephalalgia 1996; 16 (04) 257-63.
• 262 Noruzzadeh R, Modabbernia A, Aghamollaii V, Ghaffarpour M, Harirchian MH, Salahi S. et al. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. Headache 2016; 56 (01) 95-103.
• 263 Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N. et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41 (02) 119-28.
• 264 Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008; 28 (06) 585-97.
• 265 Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D’Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008; 70 (07) 548-55.
• 266 Bussone G, Cerbo R, Martucci N, Micieli G, Zanferrari C, Grazzi L. et al. Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache 1999; 39 (06) 426-31.
• 267 Schoenen J, Jacquy J, Lenaerts M. High-dose power riboflavin as a novel prophylactic antimigraine therapy: results from a double-blind, randomized, placebo-controlled trial. Cephalalgia 1997; 17: 244.
• 268 Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50 (02) 466-70.
• 269 Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D. et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64 (04) 713-5.
• 270 Slater SK, Nelson TD, Kabbouche MA, Lecates SL, Horn P, Segers A. et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31 (08) 897-905.
• 271 Gaul C, Diener HC, Danesch U. Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015; 16: 516.
• 272 Chilson CN, Brown SJ. Role of botulinum toxin type A in the prophylactic treatment of migraine headaches. Ann Pharmacother 2005; 39 (12) 2081-5.
• 273 Shuhendler AJ, Lee S, Siu M, Ondovcik S, Lam K, Alabdullatif A. et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009; 29 (07) 784-91.
• 274 Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A – a review according to evidence-based medicine criteria. Cephalalgia 2002; 22 (09) 699-710.
• 275 Petri S, Tolle T, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A. et al. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol 2009; 62 (04) 204-11.
• 276 Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40 (06) 445-50.
• 277 Gupta VK. Botulinum toxin – a treatment for migraine? A systematic review. Pain Med 2006; 07 (05) 386-94.
• 278 Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS. et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1707-14.
• 279 Conway S, Delplanche C, Crowder J, Rothrock J. Botox therapy for refractory chronic migraine. Headache 2005; 45 (04) 355-7.
• 280 Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80 (09) 1126-37.
• 281 Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (07) 804-14.
• 282 Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (07) 793-803.
• 283 Aurora SK, Dodick DW, Diener HC, Degryse RE, Turkel CC, Lipton RB. et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 2014; 129 (01) 61-70.
• 284 Diener H, Dodick D, DeGryse R, Turkel C. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-Week Pooled subgroup analysis of patients without medication overuse (Abstract). J Headache Pain. 2012 3rd European Headache and Migraine Trust International Congress – EHMTIC, September 20–23, 2012.
• 285 Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (06) 921-36.
• 286 Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45 (04) 315-24.
• 287 Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008; 48 (02) 210-20.
• 288 Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009; 49 (10) 1466-78.
• 289 Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 2010; 112 (06) 463-6.
• 290 Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011; 51 (01) 21-32.
• 291 Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a metaanalysis. JAMA 2012; 307 (16) 1736-45.
• 292 Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain 2015; 17 (01) 48.
• 293 Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. Cephalalgia 2015; 35 (10) 864-868.
• 294 Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. Bmj 2001; 322 (7277): 19-22.
• 295 Diener HC, Gendolla A, Feuersenger A, Evers S, Straube A, Schumacher H. et al. Telmisartan in migraine prophylaxis: a randomized, placebocontrolled trial. Cephalalgia 2009; 29 (09) 921-7.
• 296 Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289 (01) 65-9.
• 297 Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2014; 34 (07) 523-32.
• 298 Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology 1994; 44 (10 Suppl 7): S17-22.
• 299 Breslau N, Schultz L, Stewart W, Lipton RB, Lucia V, Welch K. Headache and major depression. Is the association specific to migraine?. Neurology 2000; 54 (02) 308-13.
• 300 Breslau N, Lipton R, Stewart W, Schultz L, Welch K. Comorbidity of migraine and depression investigating potential etiology and prognosis. Neurology 2003; 60 (08) 1308-12.
• 301 Merikangas KR, Stevens DE. Comorbidity of migraine and psychiatric disorders. Neurol Clin 1997; 15 (01) 115-23.
• 302 Lipton RB, Hamelsky SW, Kolodner KB, Steiner T, Stewart WF. Migraine, quality of life, and depression A population-based case-control study. Neurology 2000; 55 (05) 629-35.
• 303 Oedegaard K, Neckelmann D, Mykletun A, Dahl A, Zwart J, Hagen K. et al. Migraine with and without aura: association with depression and anxiety disorder in a population based study. The HUNT Study. Cephalalgia 2006; 26 (01) 1-6.
• 304 Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache: The Journal of Head and Face Pain 2006; 46 (09) 1334-43.
• 305 Radat F, Creac’h C, Swendsen J, Lafittau M, Irachabal S, Dousset V. et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25 (07) 519-22.
• 306 Gudmundsson LS, Scher AI, Sigurdsson S, Geerlings MI, Vidal J-S, Eiriksdottir G. et al. Migraine, depression, and brain volume The AGES-Reykjavik Study. Neurology 2013; 80 (23) 2138-44.
• 307 McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004; 111 (01) 77-83.
• 308 Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of Migraine and Psychiatric Disorders – A National Population Based Study. Headache: The Journal of Head and Face Pain 2008; 48 (04) 501-16.
• 309 Zarei MR, Shabani M, Chamani G, Abareghi F, Razavinasab M, Nazeri M. Migraine patients have a higher prevalence of PTSD symptoms in comparison to chronic tension-type headache and healthy subjects: a case-control study. Acta Odontologica Scandinavica. 2016: 1-3.
• 310 Bigal M, Lipton R, Cohen J, Silberstein S. Epilepsy and migraine. Epilepsy & Behavior 2003; 04: 13-24.
• 311 Leniger T, Von Den Driesch S, Isbruch K, Diener HC, Hufnagel A. Clinical characteristics of patients with comorbidity of migraine and epilepsy. Headache: The Journal of Head and Face Pain 2003; 43 (06) 672-7.
• 312 Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol 2005; 18 (03) 305-10.
• 313 Le H, Tfelt-Hansen P, Russell MB, Skytthe A, Kyvik KO, Olesen J. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia 2011; 31 (01) 43-64.
• 314 Rajapakse T, Buchhalter J. The borderland of migraine and epilepsy in children. Headache: The Journal of Head and Face Pain 2016; 56 (06) 1071-1080.
• 315 Mainieri G, Cevoli S, Giannini G, Zummo L, Leta C, Broli M. et al. Headache in epilepsy: prevalence and clinical features. The journal of headache and pain 2015; 16 (01) 1.
• 316 Förderreuther S, Henkel A, Noachtar S, Straube A. Headache associated with epileptic seizures: epidemiology and clinical characteristics. Headache: the Journal of Head and Face Pain 2002; 42 (07) 649-55.
• 317 Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. Bmj 2008; 337: a636.
• 318 Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. Jama 2006; 296 (03) 283-91.
• 319 Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC. et al. Migraine and risk of cardiovascular disease in men. Archives of Internal Medicine 2007; 167 (08) 795-801.
• 320 Kurth T. Migraine and ischaemic vascular events. Cephalalgia 2007; 27 (08) 965-75.
• 321 Bigal M, Kurth T, Santanello N, Buse D, Golden W, Robbins M. et al. Migraine and cardiovascular disease. A population-based study. Neurology 2010; 74 (08) 628-35.
• 322 Chang C, Donaghy M, Poulter N. World Health Organisation Collaborative Study of cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: casecontrol study. BMJ 1999; 318 (7175): 13-8.
• 323 Buettner C, Nir RR, Bertisch SM, Bernstein C, Schain A, Mittleman MA. et al. Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Annals of neurology 2015; 78 (06) 970-81.
• 324 Steiner T, Findley L, Yuen A. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17 (02) 109-12.
• 325 Lampl C, Katsarava Z, Diener H, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. Journal of Neurology, Neurosurgery & Psychiatry 2005; 76 (12) 1730-2.
• 326 d’Amato C, DeMarco N, Pizza V. Migraine with and without aura as same or two different disorders: clinical evidence and response to flunarizine. Headache Quarterly-Current Treatment and Research 1996; 07 (01) 43-7.
• 327 Reuter U, Del Rio MS, Diener HC, Allais G, Davies B, Gendolla A. et al. Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia 2010; 30 (05) 543-551.
• 328 Pelzer N, Stam AH, Carpay JA, de Vries B, van den Maagdenberg AM, Ferrari MD. et al. Familial hemiplegic migraine treated by sodium valproate and lamotrigine. Cephalalgia 2014; 34 (09) 708-11.
• 329 Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. The Lancet Neurology 2011; 10 (05) 457-70.
• 330 Victor S, Ryan S. Drugs for preventing migraine headaches in children. The Cochrane Library. 2003
• 331 Damen L, Bruijn J, Verhagen A, Berger M, Passchier J, Koes B. Prophylactic treatment of migraine in children. Part 2. A systematic review of pharmacological trials. Cephalalgia 2006; 26 (05) 497-505.
• 332 Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate for Migraine Prevention in Children: A Randomized, Double Blind, Placebo Controlled Trial. Headache: The Journal of Head and Face Pain 2005; 45 (10) 1304-12.
• 333 Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP. et al. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache: The Journal of Head and Face Pain 2006; 46 (10) 1503-10.
• 334 Kacperski J. Prophylaxis of migraine in children and adolescents. Pediatric Drugs 2015; 17 (03) 217-26.
• 335 Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW. et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med. 2016
• 336 Le K, Yu D, Wang J, Ali AI, Guo Y. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain 2017; 18 (01) 69.
• 337 Apostol G, Cady RK, Laforet GA, Robieson WZ, Olson E, Abi WMSaab. et al. Divalproex Extended Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double Blind, Placebo Controlled Study. Headache: The Journal of Head and Face Pain 2008; 48 (07) 1012-25.
• 338 Schroeder A, Huss K, Blaschek A, Koerte I, Zeycan B, Roser T. et al. Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain. Neuropediatrics 2012; 43 (06) 339-45.
• 339 Bernhard M, Bertsche A, Syrbe S, Weise S, Merkenschlager A. [Botulinum toxin injections for chronic migraine in adolescents – an early therapeutic option in the transition from neuropaediatrics to neurology]. Fortschritte der Neurologie-Psychiatrie 2014; 82 (01) 39-42.
• 340 Aicua-Rapun I, Martinez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A. et al. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year. J Headache Pain 2016; 17 (01) 112.
• 341 Stubberud A, Varkey E, McCrory DC, Pedersen SA, Linde M. Biofeedback as Prophylaxis for Pediatric Migraine: A Meta-analysis. Pediatrics 2016; 138 (02) e20160675.
• 342 Sances G, Granella F, Nappi R, Fignon A, Ghiotto N, Polatti F. et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23 (03) 197-205.
• 343 Kvisvik EV, Stovner LJ, Helde G, Bovim G, Linde M. Headache and migraine during pregnancy and puerperium: the MIGRA-study. The journal of headache and pain 2011; 12 (04) 443-51.
• 344 Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy. CNS drugs 2005; 19 (06) 465-81.
• 345 Tepper D. Pregnancy and lactation – migraine management. Headache: The Journal of Head and Face Pain 2015; 55 (04) 607-8.
• 346 Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. Military medicine 2014; 179 (06) e703-e4.
• 347 Govindappagari S, Grossman TB, Dayal AK, Grosberg BM, Vollbracht S, Robbins MS. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstetrics & Gynecology 2014; 124 (06) 1169-74.
• 348 Brandes JL, Poole A, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD. et al. Short-term frovatriptan for the prevention of difficult-totreat menstrual migraine attacks. Cephalalgia: an international journal of headache 2009; 29 (11) 1133-48.
• 349 Brandes JL, Smith T, Diamond M, Ames MH. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. Headache 2007; 47 (06) 886-94.
• 350 MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B. et al. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache 2009; 49 (09) 1298-314.
• 351 Moschiano F, Allais G, Grazzi L, Usai S, Benedetto C, D’Amico D. et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci 2005; 26 (Suppl. 02) s162-6.
• 352 Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG. et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001; 41 (03) 248-56.
• 353 Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990; 30 (11) 705-9.
• 354 Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache 2009; 49 (09) 1283-97.
• 355 Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63 (02) 261-9.
• 356 Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebocontrolled study. CNS Drugs 2008; 22 (10) 877-86.
• 357 Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008; 70 (17) 1555-63.
• 358 MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006; 67 (12) 2159-63.
• 359 Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception 2010; 82 (06) 497-502.
• 360 Teichmann A, Apter D, Emerich J, Greven K, Klasa-Mazurkiewicz D, Melis GB. et al. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception 2009; 80 (06) 504-11.
• 361 Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75 (06) 444-9.
• 362 Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47 (01) 27-37.
• 363 Kurth T. Migraine is a marker for risk of both ischaemic and haemorrhagic stroke. Evidencebased medicine 2014; 19 (04) 156.
• 364 Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB. et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016; 353: i2610.
• 365 Sacco S, Merki-Feld GS, Aegidius AE, Bitzer J, Canonico M, Kurth T. et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain 2017; 18 (01) 108.
• 366 Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. Headache 2018; 58 (01) 5-21.
• 367 Tepper NK, Whiteman MK, Zapata LB, Marchbanks PA, Curtis KM. Safety of hormonal contraceptives among women with migraine: A systematic review. Contraception 2016; 94 (06) 630-40.
• 368 Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44: 647-51.
• 369 Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007; 115 (02) 81-3.
• 370 Martinez HR, Londono O, Cantu-Martinez L, del Carmen LTarin, Castillo CD. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache 2003; 43 (10) 1080-4.
• 371 Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003; 23 (10) 961-2.
• 372 Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg 2008; 110 (10) 979-84.
• 373 Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A. et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain 2014; 15: 47.
• 374 Lampl C, Jensen R, Martelletti P, Mitsikostas DD. Refractory headache: one term does not cover all – a statement of the European Headache Federation. J Headache Pain 2014; 15: 50.
• 375 Gaul C, Holle D, Sandor PS, Evers S, Broessner G, Straube A. et al. [The value of “migraine surgery”. Overview of the pathophysiological concept and current evidence]. Nervenarzt 2010; 81 (04) 463-70.
• 376 Tariq N, Tepper SJ, Kriegler JS. Patent Foramen Ovale and Migraine: Closing the Debate – A Review. Headache 2016; 56 (03) 462-78.
• 377 Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL. et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation 2008; 118 (14) 1419-24.
• 378 Kuper M, Rabe K, Holle D, Savidou I, Dommes P, Frings M. et al. Prevalence of cardiac right left shunts in migraine: a population-based casecontrol study. Neurol Sci 2013; 34 (02) 205-8.
• 379 Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C. et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008; 117 (11) 1397-404.
• 380 Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J. et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Eur Heart J 2016; 37 (26) 2029-36.
• 381 Rayhill M, Burch R. PFO and Migraine: Is There a Role for Closure?. Curr Neurol Neurosci Rep 2017; 17 (03) 20.
• 382 Tobin J, Flitman S. Occipital nerve blocks: when and what to inject?. Headache 2009; 49 (10) 1521-33.
• 383 Dilli E, Halker R, Vargas B, Hentz J, Radam T, Rogers R. et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. Cephalalgia 2015; 35 (11) 959-68.
• 384 Cuadrado ML, Aledo-Serrano A, Navarro P, Lopez-Ruiz P, Fernandez-de-Las-Penas C, Gonzalez-Suarez I. et al. Short-term effects of greater occipital nerve blocks in chronic migraine: A double-blind, randomised, placebo-controlled clinical trial. Cephalalgia 2017; 37 (09) 864-872.
• 385 Inan LE, Inan N, Karadas O, Gul HL, Erdemoglu AK, Turkel Y. et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 2015; 132 (04) 270-7.
• 386 Cuadrado ML, Aledo-Serrano A, Lopez-Ruiz P, Gutierrez-Viedma A, Fernandez C, Orviz A. et al. Greater occipital nerve block for the acute treatment of prolonged or persistent migraine aura. Cephalalgia 2017; 37 (08) 812-8.
• 387 Bartsch T, Paemeleire K, Goadsby PJ. Neurostimulation approaches to primary headache disorders. Curr Opin Neurol 2009; 22 (03) 262-8.
• 388 Lipton R, Goadsby P, Cady R, Aurora S, Grosberg B, Freitag F. et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009; 29: 30.
• 389 Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. et al. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2011; 31 (03) 271-85.
• 390 Schwedt TJ. Neurostimulation for primary headache disorders. Curr Neurol Neurosci Rep 2009; 09 (02) 101-7.
• 391 Mueller O, Diener HC, Dammann P, Rabe K, Hagel V, Sure U. et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia 2013; 33 (16) 1283-91.
• 392 Mekhail NA, Estemalik E, Azer G, Davis K, Tepper SJ. Safety and Efficacy of Occipital Nerves Stimulation for the Treatment of Chronic Migraines: Randomized, Double-blind, Controlled Single-center Experience. Pain Pract 2017; 17 (05) 669-677.
• 393 Schoenen J, Allena M, Magis D. Neurostimulation therapy in intractable headaches. Handb Clin Neurol 2010; 97: 443-50.
• 394 Jurgens TP, Leone M. Pearls and pitfalls: neurostimulation in headache. Cephalalgia 2013; 33 (08) 512-25.
• 395 Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A. et al. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia 2016; 36 (06) 534-46.
• 396 Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia 2014; 34 (12) 986-93.
• 397 Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): a randomized, monocentric clinical trial. J Headache Pain 2015; 16: 543.
• 398 Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D. et al. Migraine prevention with percutaneous mastoid electrical stimulator: A randomized double-blind controlled trial. Cephalalgia; 2016
• 399 Miller S, Sinclair AJ, Davies B, Matharu M. Neurostimulation in the treatment of primary headaches. Pract Neurol 2016; 16 (05) 362-75.
• 400 Riederer F, Penning S, Schoenen J. Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly Device for Migraine Prevention: A Review of the Available Data. Pain Ther. 2015
• 401 Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P. et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 2013; 80 (08) 697-704.
• 402 Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly(R) device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 2013; 14: 95.
• 403 Di Fiore P, Bussone G, Galli A, Didier H, Peccarisi C, D’Amico D. et al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol Sci 2017 38 (Suppl. 01) 201-6.
• 404 Clarke BM, Upton AR, Kamath MV, Al-Harbi T, Castellanos CM. Transcranial magnetic stimulation for migraine: clinical effects. J Headache Pain 2006; 07 (05) 341-6.
• 405 Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH. et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 2010; 09 (04) 373-80.
• 406 Brighina F, Piazza A, Vitello G, Aloisio A, Palermo A, Daniele O. et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci 2004; 227 (01) 67-71.
• 407 Teepker M, Hotzel J, Timmesfeld N, Reis J, Mylius V, Haag A. et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia 2010; 30 (02) 137-44.
• 408 Barker AT, Shields K. Transcranial Magnetic Stimulation: Basic Principles and Clinical Applications in Migraine. Headache. 2016
• 409 Shirahige L, Melo L, Nogueira F, Rocha S, Monte-Silva K. Efficacy of Noninvasive Brain Stimulation on Pain Control in Migraine Patients: A Systematic Review and Meta-Analysis. Headache 2016; 56 (10) 1565-96.
• 410 Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA. et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst Rev 2016; 06: CD001218
• 411 Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009; 01: CD001218
• 412 Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL. et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia 2011; 31 (15) 1510-21.
• 413 Coeytaux RR, Kaufman JS, Kaptchuk TJ, Chen W, Miller WC, Callahan LF. et al. A randomized, controlled trial of acupuncture for chronic daily headache. Headache 2005; 45 (09) 1113-23.
• 414 Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N. et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 2004; 328 7442: 744.
• 415 Endres HG, Diener HC, Molsberger A. Role of acupuncture in the treatment of migraine. Expert Rev Neurother 2007; 07 (09) 1121-34.
• 416 Ernst E. Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom Manage 1999; 18 (05) 353-7.
• 417 Walach H, Haeusler W, Lowes T, Mussbach D, Schamell U, Springer W. et al. Classical Homeopathic Treatment of Chronic Headaches. Cephalalgia 1997; 17 (02) 119-26.
• 418 Walach H, Lowes T, Mussbach D, Schamell U, Springer W, Stritzl G. et al. The Long-Term Effects of Homeopathic Treatment of Chronic Headaches: 1 Year Follow Up. Cephalalgia 2000; 20 (09) 835-7.
• 419 Whitmarsh TE, Coleston-Shields DM, Steiner TJ. Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 1997; 17 (05) 600-4.
• 420 Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology 2006; 66 (04) 545-50.
• 421 Busch V, Gaul C. Exercise in migraine therapy – is there any evidence for efficacy? A critical review. Headache 2008; 48 (06) 890-9.
• 422 Baillie LE, Gabriele JM, Penzien DB. A systematic review of behavioral headache interventions with an aerobic exercise component. Headache 2014; 54 (01) 40-53.
• 423 Darabaneanu S, Overath CH, Rubin D, Luthje S, Sye W, Niederberger U. et al. Aerobic exercise as a therapy option for migraine: a pilot study. Int J Sports Med 2011; 32 (06) 455-60.
• 424 Overath CH, Darabaneanu S, Evers MC, Gerber WD, Graf M, Keller A. et al. Does an aerobic endurance programme have an influence on information processing in migraineurs?. J Headache Pain 2014; 15: 11.
• 425 Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011; 31 (14) 1428-38.
• 426 Kropp P, Niederberger U. Schmerz. In: Brähler E, Strauß B. editors. Grundlagen der Medizinischen Psychologie – Medizinische Psychologie. Göttingen: Hogrefe; 2012
• 427 Kropp P, Dresler T, Niederberger U. Psychosomatik der Kopfschmerzen. Psychotherapeut 2014; 59 (01) 57-71.
• 428 Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010; 09 (03) 285-98.
• 429 Kropp P, Meyer B, Dresler T, Fritsche G, Gaul C, Niederberger U. et al. Entspannungsverfahren und therapeutische Interventionen zur Behandlung der Migräne. Leitlinie der Deutschen Migräne- und Kopfschmerzgesellschaft. Der Schmerz 2017; 35: 433-447.
• 430 Gaul C, Liesering-Latta E, Schafer B, Fritsche G, Holle D. Integrated multidisciplinary care of headache disorders: A narrative review. Cephalalgia 2016; 36 (12) 1181-91.
• 431 Seng EK, Holroyd KA. Dynamics of changes in self-efficacy and locus of control expectancies in the behavioral and drug treatment of severe migraine. Ann Behav Med 2010; 40 (03) 235-47.
• 432 Silberstein SD. Practice parameter: evidencebased guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55 (06) 754-62.
• 433 Andrasik F. Behavioral treatment of headaches: extending the reach. Neurol Sci 2012; 33 (Suppl. 01) S127-30.
• 434 Frettlöh J, Franz C, Jäkle C, Kröner-Herwig B, Peters-Knäbel K, Rehfisch HP. et al. Das Manual. In: Basler HD, Kröner-Herwig B. editors. Psychologische Therapie bei Kopf- und Rückenschmerzen. München: Quintessenz; 1998
• 435 Scharff L, Marcus DA. Interdisciplinary outpatient group treatment of intractable headache. Headache 1994; 34 (02) 73-8.
• 436 Haddock CK, Rowan AB, Andrasik F, Wilson PG, Talcott GW, Stein RJ. Home-based behavioral treatments for chronic benign headache: a meta-analysis of controlled trials. Cephalalgia 1997; 17 (02) 113-8.
• 437 Gaul C, van Doorn C, Webering N, Dlugaj M, Katsarava Z, Diener HC. et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain 2011; 12 (04) 475-83.
• 438 Gaul C, Visscher CM, Bhola R, Sorbi MJ, Galli F, Rasmussen AV. et al. Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. J Headache Pain 2011; 12 (05) 511-9.
• 439 Wallasch TM, Kropp P. Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. J Headache Pain 2012; 13 (07) 521-9.
• 440 Connelly M, Rapoff MA, Thompson N, Connelly W. Headstrong: a pilot study of a CD-ROM intervention for recurrent pediatric headache. J Pediatr Psychol 2006; 31 (07) 737-47.
• 441 McGrath PJ, Humphreys P, Keene D, Goodman JT, Lascelles MA, Cunningham SJ. et al. The efficacy and efficiency of a self-administered treatment for adolescent migraine. Pain 1992; 49 (03) 321-4.
• 442 Cuijpers P, van Straten A, Andersson G. Internet-administered cognitive behavior therapy for health problems: a systematic review. J Behav Med 2008; 31 (02) 169-77.
• 443 Hedborg K, Muhr C. Multimodal behavioral treatment of migraine: an Internet-administered, randomized, controlled trial. Ups J Med Sci 2011; 116 (03) 169-86.
• 444 Trautmann E, Kröner-Herwig B. A randomized controlled trial of Internet-based self-help training for recurrent headache in childhood and adolescence. Behav Res Ther 2010; 48 (01) 28-37.
• 445 Goslin RE, Gray RN, McCrory DC, Penzien D, Rains J, Hasselblad V. Behavioral and Physical Treatments for Migraine Headache. Behavioral and Physical Treatments for Migraine Headache. AHRQ Technical Reviews. Rockville (MD): 1999
• 446 Sullivan A, Cousins S, Ridsdale L. Psychological interventions for migraine: a systematic review. J Neurol 2016; 263 (12) 2369-77.
• 447 Harris P, Loveman E, Clegg A, Easton S, Berry N. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain 2015; 09 (04) 213-24.
• 448 Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain 2007; 128 (1–2): 111-27.
• 449 Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback 2008; 33 (03) 125-40.
• 450 Andrasik F. Biofeedback in headache: an overview of approaches and evidence. Cleve Clin J Med 2010; 77 (Suppl. 03) S72-6.
• 451 Andrasik F. Behavioral treatment of migraine: current status and future directions. Expert Rev Neurother 2004; 04 (03) 403-13.
• 452 Adachi T, Fujino H, Nakae A, Mashimo T, Sasaki J. A meta-analysis of hypnosis for chronic pain problems: a comparison between hypnosis, standard care, and other psychological interventions. Int J Clin Exp Hypn 2014; 62 (01) 1-28.
• 453 Penzien DB, Andrasik F, Freidenberg BM, Houle TT, Lake 3rd AE, Lipchik GL. et al. Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache 2005; 45 (Suppl. 02) S110-32.
• 454 Penzien DB, Irby MB, Smitherman TA, Rains JC, Houle TT. Well-Established and Empirically Supported Behavioral Treatments for Migraine. Current Pain and Headache Reports 2015; 19 (07) 34.
• 455 Meyer B, Keller A, Wohlbier HG, Overath CH, Muller B, Kropp P. Progressive muscle relaxation reduces migraine frequency and normalizes amplitudes of contingent negative variation (CNV). J Headache Pain 2016; 17: 37.
• 456 French DJ, Holroyd KA, Pinell C, Malinoski PT, O’Donnell F, Hill KR. Perceived self-efficacy and headache-related disability. Headache 2000; 40 (08) 647-56.
• 457 Kropp P, Klinger R, Dresler T. [Headaches diary, weekends, chocolate and red wine: are expectations the leading migraine trigger?]. MMW Fortschr Med 2015; 157 (02) 62-4.
• 458 Fritsche G, Frettloh J, Huppe M, Dlugaj M, Matatko N, Gaul C. et al. Prevention of medication overuse in patients with migraine. Pain 2010; 151 (02) 404-13.
• 459 Fritsche G, Kroner-Herwig B, Kropp P, Niederberger U, Haag G. [Psychological therapy of migraine: systematic review]. Schmerz 2013; 27 (03) 263-74.
• 460 Andrasik F, Grazzi L, Usai S, Buse DC, Bussone G. Non-pharmacological approaches to treating chronic migraine with medication overuse. Neurol Sci 2009; 30 (Suppl. 01) S89-93.
• 461 Holroyd KA, Cottrell CK, O’Donnell FJ, Cordingley GE, Drew JB, Carlson BW. et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. Bmj 2010; 341: c4871.
• 462 Smitherman TA, Penzien DB, Maizels M. Anxiety disorders and migraine intractability and progression. Curr Pain Headache Rep 2008; 12 (03) 224-9.
• 463 Holroyd KA, Drew JB. Behavioral approaches to the treatment of migraine. Semin Neurol 2006; 26 (02) 199-207.
• 464 Sorbi MJ, Mak SB, Houtveen JH, Kleiboer AM, van Doornen LJ. Mobile Web-based monitoring and coaching: feasibility in chronic migraine. J Med Internet Res 2007; 09 (05) e38.
• 465 Merelle SY, Sorbi MJ, van Doornen LJ, Passchier J. Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial. Cephalalgia 2008; 28 (02) 127-38.
• 466 Lewis DW. Pediatric migraine. Neurol Clin 2009; 27 (02) 481-501.
• 467 Grazzi L, Andrasik F, D’Amico D, Leone M, Usai S, Kass SJ. et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002; 42 (06) 483-90.
• 468 Rogers AMM, Lemmen K, Kramer R, Mann J, Chopra V. Internet-Delivered Health Interventions That Work: Systematic Review of Meta-Analyses and Evaluation of Website Availability. J Med Internet Res 2017; 19 (03) e90.
• 469 Mosadeghi-Nik M, Askari MS, Fatehi F. Mobile health (mHealth) for headache disorders: A review of the evidence base. J Telemed Telecare 2016; 22 (08) 472-7.
• 470 Minen MT, Torous J, Raynowska J, Piazza A, Grudzen C, Powers S. et al. Electronic behavioral interventions for headache: a systematic review. J Headache Pain 2016; 17: 51.
• 471 Hundert AS, Huguet A, McGrath PJ, Stinson JN, Wheaton M. Commercially available mobile phone headache diary apps: a systematic review. JMIR Mhealth Uhealth 2014; 02 (03) e36.
• 472 Fisher E, Law E, Palermo TM, Eccleston C. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev 2015; 03: CD011118
• 473 Eccleston C, Fisher E, Craig L, Duggan GB, Rosser BA, Keogh E. Psychological therapies (Internet-delivered) for the management of chronic pain in adults. Cochrane Database Syst Rev 2014; 02: CD010152
• 474 Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: A systematic review. Internet Interventions 2016; 04: 17-34.
• 475 Gaul C, Eismann R, Schmidt T, May A, Leinisch E, Wieser T. et al. Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia 2009; 29 (10) 1069-78.
• 476 Alpay K, Ertas M, Orhan EK, Ustay DK, Lieners C, Baykan B. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia 2010; 30 (07) 829-37.
• 477 Posadzki P, Ernst E. Spinal manipulations for the treatment of migraine: a systematic review of randomized clinical trials. Cephalalgia 2011; 31 (08) 964-70.
• 478 Goncalves DA, Bigal ME, Jales LC, Camparis CM, Speciali JG. Headache and symptoms of temporomandibular disorder: an epidemiological study. Headache 2010; 50 (02) 231-41.